CellProthera acquires catheter technology to enhance delivery of its ProtheraCytes therapy, advancing Phase III clinical ...
Strategic acquisition secures proprietary stem cell delivery technology as CellProthera prepares for Phase 3 clinical ...
Regulatory News: Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), today announced the acquisition by ...
For most of his 20 years, a New Jersey man knew pain as a daily reality. Now, after a one-time CRISPR gene-editing treatment at Children's Hospital of Philadelphia, Austin Louis says he is finally ...
Treatments for acquired hypothalamic obesity, dry eye disease, primary biliary cholangitis, psoriatic arthritis, and severe leukocyte adhesion deficiency-I under review.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results